News Search Results
Jun 03, 2026, 16:05 ET ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily
More news about: ADC Therapeutics SA
Jun 03, 2026, 10:01 ET T-cell Malignancies Market to Accelerate Substantially at a CAGR of 5.2% During the Forecast Period (2026-2036) | DelveInsight
immune defense. These malignancies include both T-cell leukemias and T-cell lymphomas, such as peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), anaplastic large cell lymphoma (ALCL), and T-cell acute lymphoblastic leukemia (T-ALL). Although relatively rare compared to B-cell cancers,
More news about: DelveInsight Business Research, LLP
Jun 03, 2026, 00:03 ET Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
articular, muscular, peripheral nervous system (PNS), central nervous system (CNS), hematological, glandular, constitutional, lymphadenopathy and lymphoma; a higher score indicates greater symptom severity.ABOUT DAHLIAS DAHLIAS (
More news about: Johnson & Johnson
Jun 02, 2026, 09:30 ET Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This
More news about: Eli Lilly and Company
Jun 02, 2026, 07:30 ET Kazia Therapeutics Appoints James Levine as Chief Financial Officer
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Jun 01, 2026, 09:00 ET SUBARU LOVES TO CARE® PROVIDES WARMTH, LOVE, AND SUPPORT TO CANCER PATIENTS IN PARTNERSHIP WITH BLOOD CANCER UNITED
Inc. (SOA) today announced that, in over 10 years of partnership as the largest automotive donor to Blood Cancer United® (formerly The Leukemia & Lymphoma Society), Subaru and its retailers will have supported more than 550,000 cancer patients and their families nationwide. Through the
More news about: Subaru of America, Inc.
Jun 01, 2026, 07:00 ET Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
use of LYMPHIR in this study was investigational and outside of its FDA-approved indication of relapsed or refractory Stage I–III cutaneous T-cell lymphoma. LYMPHIR is not approved by the FDA for the treatment of gynecologic malignancies or any solid tumor, and the safety and efficacy of LYMPHIR in this
More news about: Citius Oncology, Inc.
Jun 01, 2026, 06:00 ET Phothera® Supports Vitiligo Awareness Month with "Shine a Light on Vitiligo" Campaign
manufacturer of FDA-cleared phototherapy devices for chronic skin conditions including vitiligo, psoriasis, atopic dermatitis, and cutaneous T-cell lymphoma (CTCL), today announced its support of Vitiligo Awareness Month with the launch of its campaign, "Shine a Light on Vitiligo, Powered by Phothera."
More news about: Phothera
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR
More news about: Dizal Pharmaceutical
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
(KEYTRUDA®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech
More news about: Kelun-Biotech
May 30, 2026, 08:00 ET GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
2026 May 29-June 2.2 The 12 cancer types include anus, bladder, colorectal, esophagus, head and neck, liver/bile duct, lung, lymphoma, myeloma/plasma cell neoplasm, ovary, pancreas, stomach.3 Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted
More news about: GRAIL, Inc.
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
(KEYTRUDA®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech
More news about: Kelun-Biotech
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
discontinuation and fixed duration therapy with the combination of VENCLYXTO plus ibrutinib in adult patients with previously untreated CLL or small lymphocytic lymphoma (SLL).7Results showed that the fixed-duration combination regimen of VENCLYXTO plus ibrutinib demonstrated 5.5-year PFS and overall
More news about: AbbVie
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
discontinuation and fixed duration therapy with the combination of VENCLYXTO plus ibrutinib in adult patients with previously untreated CLL or small lymphocytic lymphoma (SLL).7Results showed that the fixed-duration combination regimen of VENCLYXTO plus ibrutinib demonstrated 5.5-year PFS and overall
More news about: AbbVie
May 29, 2026, 00:55 ET 페프로민 바이오, 이전 CD19 CAR T세포 치료 실패 후를 포함한 B세포 림프종에서 PMB-CT01(BAFF-R CAR T세포 치료제)의 우수한 안전성과 지속적인 반응을 강조하는 EHA 2026 구두 발표 예고
질환(minimal residual disease, MRD) 음성 상태를 달성해, 검출 가능한 잔류 암세포가 없는 깊은 관해를 나타냈다.이러한 결과를 바탕으로 해당 임상시험은 외투 세포 림프종, 거대 B세포 림프종 및 소포성 림프종(follicular lymphoma, FL)에 대한 확장 코호트 환자 등록을 활발히 진행하고 있다. 특히 이번 확장 단계에서 치료를 받은 첫 번째 환자인 CD19 CAR T 치료 후 질병이 진행된 형질전환 FL(transformed FL, tFL) 환자는 첫 번째 질병 평가에서 CR에 도달했다. tFL은
More news about: PeproMene Bio, Inc.
May 28, 2026, 12:30 ET Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
Gene Panel offers rapid solid tumor and hematological malignancy sequencing for multiple cancer types including NSCLC, endometrial, AML, B-Cell Lymphoma and MPN.The oncoReveal® Lymphoid Panel is an 84 gene DNA panel spanning high-value B-cell, T-cell, and lymphoblastic
More news about: Illumina, Inc.
May 28, 2026, 10:35 ET Florida Cancer Specialists & Research Institute Study Finds Comparable Quality and Safety Outcomes in CAR T-Cell Therapy Across Accredited and Non-Accredited Centers, Highlighting Care Location as Key Driver of Patient Access and Experience
This important study compared more than 6,800 adult patients with diffuse large b-cell lymphoma receiving CAR T therapy in clinic settings accredited by the Foundation for the Accreditation of Cellular Therapy* (FACT) and non-FACT accredited
More news about: Florida Cancer Specialists & Research Institute
May 28, 2026, 08:54 ET Florida Cancer Specialists & Research Institute Advances the Future of Cancer Care
antigen receptor (CAR) T cell therapy across Foundation for the Accreditation of Cellular Therapy (FACT) and non-FACT treatment centers in large B-cell lymphoma (LBCL).*Lowell Hart, MD (Retired)(RW) post-progression outcomes following first-line (1L) ribociclib (RIB)
More news about: Florida Cancer Specialists & Research Institute
May 28, 2026, 08:00 ET Blood Cancer United Data at 2026 ASCO and EHA Highlight Beat AML Progress, Patient Experience Insights and Access Barriers
Induce High Rates of Complete Remissions with Minimal Neurotoxicity in High-Risk Follicular Lymphoma, Mantle Cell Lymphoma, and Other Non-Hodgkin Lymphoma SubtypesOral
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
May 28, 2026, 07:00 ET PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
cancer cells.Building on these results, the trial is actively enrolling patients into expansion cohorts for mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma (FL). Importantly, the first patient treated in this expansion phase – a patient with transformed FL (tFL) who had progressed
More news about: PeproMene Bio, Inc.
May 28, 2026, 07:00 ET PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
cancer cells.Building on these results, the trial is actively enrolling patients into expansion cohorts for mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma (FL). Importantly, the first patient treated in this expansion phase – a patient with transformed FL (tFL) who had progressed
More news about: PeproMene Bio, Inc.
May 27, 2026, 08:17 ET VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
First Quarter Revenue Growth: Reported $1M of revenue in the first quarter of 2026, representing a 300% increase year-over-year.Feline Lymphoma Manuscript Submission: Formally submitted the clinical manuscript for the Nu.Q® Vet cancer test in cats; $5 million milestone payment anticipated
More news about: VolitionRx Limited
May 26, 2026, 12:53 ET John Theurer Cancer Center at Hackensack University Medical Center Presents Innovative Cancer Research at Major Annual Cancer Meeting
Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile.
More news about: Hackensack Meridian John Theurer Cancer Center
May 26, 2026, 08:30 ET Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphomaIRVING, Texas, May 26, 2026 /PRNewswire/ -- Caris Life Sciences®,
More news about: Caris Life Sciences
May 26, 2026, 08:00 ET Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
tumors.About LYMPHIR™ (denileukin diftitox‑cxdl)LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2
More news about: Citius Oncology, Inc.